September 5th, 2024 (Shanghai) — We are glad to announce that Sue Soheui Choe, the Chief Executive Officer of Atheon Bio, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.
About Atheon Bio
- Innovative Science: Atheon Bio is revolutionizing immune-oncology by pushing the limits of what was once thought impossible, bringing the treatments to solid cancer patients worldwide. We introduce an innovative therapeutic strategy to address the challenge faced by solid cancer patients who do not benefit from existing immuneoncology treatments, particularly those resistant to checkpoint inhibitors.
- Novel Target in Tumor Microenvironment: Atheon Bio discovered novel target of tumor microenvironment that controls both angiogenesis and activation of immune cells. This novel target is exclusively overexpressed in tumor endothelial cells.
- Lead Asset: Our lead asset, ATN001, is a groundbreaking first-in-class antibody that inhibits a novel target of the tumor microenvironment (TME), recognized as a key player in the angiogenesis and immunosuppression seen in solid tumors. ATN001 stands out with its dual action, simultaneously regulating anti-angiogenesis and immune activation to reprogram the TME. This positions ATN001 as a novel treatment option for patients with solid cancers who have seen limited or no success with immune checkpoint inhibitors, potentially setting a new standard in how solid tumors are managed.
- Strong Intellectual Property: We have a strong IP portfolio, with three US patent applications, three PCT patent applications, and three Korean patent applications pending, providing us with a significant competitive advantage in the market.
- Experienced Team: The Atheon Bio team consists of seasoned professionals with extensive expertise in immuno-oncology, non-clinical and clinical development, business development, and technology management within the pharmaceutical and biotechnology sectors. Our team members have a proven track record of driving innovative drug developments.
- Awards and Grants: Atheon Bio has garnered significant recognition for its innovation, earning multiple prestigious awards. In May 2024, we won the QuickFire Challenge Singapore by Johnson & Johnson and became a member of JLABS Singapore. Additionally, Atheon Bio secured first place in Technology Commercialization from the Korean Pharmaceutical Association, was selected for the TIPS (Tech Incubation Program for Startup Korea), and received four government grants from the Ministry of SMEs and Startups of Korea.
- Strategic Vision: Our strategic focus is to become the global leader in tumor microenvironment research, pioneering a revolutionary approach to transforming solid cancer treatments.
About the speaker
As the CEO and Founder of Atheon Bio, Inc., a pioneering Korean startup in the development of cancer immunotherapies targeting the tumor microenvironment, Dr. Choe stands at the forefront of innovation in the biotechnology field.
With over two decades of experience in the pharmaceutical and biotechnology industries, Dr. Choe’s comprehensive expertise spans business, technology, and law, underpinning her effective corporate leadership and broad cross-industry knowledge, grounded in a robust
technical foundation.
Holding a bachelor’s degree in Chemistry from Seoul National University in Korea, Dr. Choe furthered her education with a Ph.D. in Biochemistry from the University Wisconsin Madison, USA. She also holds a J.D. from the University of Minnesota Law School, USA. Dr. Choe practiced as an intellectual property attorney in major U.S. law firms for seven years, focusing on patent law related to biochemistry, medicine, pharmaceuticals, chemistry, nanotechnology, and medical devices.
Dr. Choe’s forward-thinking strategy for commercializing technology merges intellectual
property, R&D, market analysis, business insights for new drugs, establishing biotechnology companies as frontrunners in the field of innovative drug development.
Her extensive experience and specialized knowledge have also benefitted numerous Korean startups, aiding them in identifying and forging strategic global partnerships. Dr. Choe has held executive roles in several Korean companies, leading business development and open innovation to foster growth in the global arena.
About ACCESS CHINA Partnering Forum
ACCESS CHINA Partnering Forum – Autumn Virtual Showcase is scheduled to be held on September 24th to 25th, and 27th, 2024, via Zoom webinar. This event helps biotechs/pharmas efficiently present their assets in front of 500+ healthcare companies and VCs online. During the event, audience can have access to innovative pharma and healthcare products from worldwide.
Conference Name: ACCESS CHINA Partnering Forum
Date & Time: Sep 24 – 25 (live), and 27 (VoD) 2024, China time
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 500+ participants Online; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs
View more information at https://biotochina.org/
REGISTER
To Register for ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
Wxiang@yafocapital.com
BioToChina.org 